A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration

Masataka Nakamura, Kevin F. Bieniek, Wen Lang Lin, Neill R Graff Radford, Melissa E Murray, Monica Castanedes-Casey, Pamela Desaro, Matthew C. Baker, Nicola J. Rutherford, Janice Robertson, Rosa V Rademakers, Dennis W Dickson, Kevin B. Boylan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Amyotrophic lateral sclerosis (ALS) is a degenerative disorder affecting upper and lower motor neurons, but it is increasingly recognized to affect other systems, with cognitive impairment resembling frontotemporal dementia (FTD) in some patients. We report clinical and pathologic findings of a family with ALS due to a truncating mutation, p.Gly141X, in copper/zinc superoxide dismutase (SOD1). The proband presented clinically with FTD and later showed progressive motor neuron disease, while all other family members had early-onset and rapidly progressive ALS without significant cognitive deficits. Pathologic examination of both the proband and her daughter revealed degeneration of corticospinal tracts and motor neurons in brain and spinal cord compatible with ALS. On the other hand, the proband also had neocortical and limbic system degeneration with pleomorphic neuronal cytoplasmic inclusions. Extramotor pathology in her daughter was relatively restricted to the hypothalamus and extrapyramidal system, but not the neocortex. The inclusions in the proband and her daughter were immunoreactive for SOD1, but negative for TAR DNA-binding protein of 43 kDa (TDP-43). In the proband, a number of the neocortical inclusions were immunopositive for α-internexin, initially suggesting a diagnosis of atypical FTLD, but there was no evidence of fused in sarcoma (FUS) immunoreactivity, which is often detected in atypical FTLD. Analogous to atypical FTLD, neuronal inclusions had variable co-localization of SOD1 and α-internexin. The current classification of FTLD is based on the major constituent protein: FTLD-tau, FTLD-TDP-43, and FTLD-FUS. The proband in this family indicates that SOD1, while rare, can also be the substrate of FTLD, in addition to the more common presentation of ALS. The explanation for clinical and pathologic heterogeneity of SOD1 mutations, including the p.Gly141X mutation, remains unresolved.

Original languageEnglish (US)
Pages (from-to)145-157
Number of pages13
JournalActa Neuropathologica
Volume130
Issue number1
DOIs
StatePublished - Apr 28 2015

Fingerprint

Frontotemporal Lobar Degeneration
Amyotrophic Lateral Sclerosis
Mutation
Nuclear Family
Frontotemporal Dementia
DNA-Binding Proteins
Motor Neurons
Sarcoma
tau Proteins
Limbic System
Motor Neuron Disease
Pyramidal Tracts
Neocortex
Inclusion Bodies
Hypothalamus
Superoxide Dismutase
Zinc
Copper
Spinal Cord
Pathology

Keywords

  • Amyotrophic lateral sclerosis
  • Electron microscopy
  • Frontotemporal lobar degeneration
  • Immunohistochemistry
  • Internexin-alpha
  • Neurofilament
  • Superoxide dismutase 1

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Cellular and Molecular Neuroscience

Cite this

A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration. / Nakamura, Masataka; Bieniek, Kevin F.; Lin, Wen Lang; Graff Radford, Neill R; Murray, Melissa E; Castanedes-Casey, Monica; Desaro, Pamela; Baker, Matthew C.; Rutherford, Nicola J.; Robertson, Janice; Rademakers, Rosa V; Dickson, Dennis W; Boylan, Kevin B.

In: Acta Neuropathologica, Vol. 130, No. 1, 28.04.2015, p. 145-157.

Research output: Contribution to journalArticle

Nakamura, Masataka ; Bieniek, Kevin F. ; Lin, Wen Lang ; Graff Radford, Neill R ; Murray, Melissa E ; Castanedes-Casey, Monica ; Desaro, Pamela ; Baker, Matthew C. ; Rutherford, Nicola J. ; Robertson, Janice ; Rademakers, Rosa V ; Dickson, Dennis W ; Boylan, Kevin B. / A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration. In: Acta Neuropathologica. 2015 ; Vol. 130, No. 1. pp. 145-157.
@article{600c25aa6ce64666abb5a5e725954660,
title = "A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration",
abstract = "Amyotrophic lateral sclerosis (ALS) is a degenerative disorder affecting upper and lower motor neurons, but it is increasingly recognized to affect other systems, with cognitive impairment resembling frontotemporal dementia (FTD) in some patients. We report clinical and pathologic findings of a family with ALS due to a truncating mutation, p.Gly141X, in copper/zinc superoxide dismutase (SOD1). The proband presented clinically with FTD and later showed progressive motor neuron disease, while all other family members had early-onset and rapidly progressive ALS without significant cognitive deficits. Pathologic examination of both the proband and her daughter revealed degeneration of corticospinal tracts and motor neurons in brain and spinal cord compatible with ALS. On the other hand, the proband also had neocortical and limbic system degeneration with pleomorphic neuronal cytoplasmic inclusions. Extramotor pathology in her daughter was relatively restricted to the hypothalamus and extrapyramidal system, but not the neocortex. The inclusions in the proband and her daughter were immunoreactive for SOD1, but negative for TAR DNA-binding protein of 43 kDa (TDP-43). In the proband, a number of the neocortical inclusions were immunopositive for α-internexin, initially suggesting a diagnosis of atypical FTLD, but there was no evidence of fused in sarcoma (FUS) immunoreactivity, which is often detected in atypical FTLD. Analogous to atypical FTLD, neuronal inclusions had variable co-localization of SOD1 and α-internexin. The current classification of FTLD is based on the major constituent protein: FTLD-tau, FTLD-TDP-43, and FTLD-FUS. The proband in this family indicates that SOD1, while rare, can also be the substrate of FTLD, in addition to the more common presentation of ALS. The explanation for clinical and pathologic heterogeneity of SOD1 mutations, including the p.Gly141X mutation, remains unresolved.",
keywords = "Amyotrophic lateral sclerosis, Electron microscopy, Frontotemporal lobar degeneration, Immunohistochemistry, Internexin-alpha, Neurofilament, Superoxide dismutase 1",
author = "Masataka Nakamura and Bieniek, {Kevin F.} and Lin, {Wen Lang} and {Graff Radford}, {Neill R} and Murray, {Melissa E} and Monica Castanedes-Casey and Pamela Desaro and Baker, {Matthew C.} and Rutherford, {Nicola J.} and Janice Robertson and Rademakers, {Rosa V} and Dickson, {Dennis W} and Boylan, {Kevin B.}",
year = "2015",
month = "4",
day = "28",
doi = "10.1007/s00401-015-1431-2",
language = "English (US)",
volume = "130",
pages = "145--157",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration

AU - Nakamura, Masataka

AU - Bieniek, Kevin F.

AU - Lin, Wen Lang

AU - Graff Radford, Neill R

AU - Murray, Melissa E

AU - Castanedes-Casey, Monica

AU - Desaro, Pamela

AU - Baker, Matthew C.

AU - Rutherford, Nicola J.

AU - Robertson, Janice

AU - Rademakers, Rosa V

AU - Dickson, Dennis W

AU - Boylan, Kevin B.

PY - 2015/4/28

Y1 - 2015/4/28

N2 - Amyotrophic lateral sclerosis (ALS) is a degenerative disorder affecting upper and lower motor neurons, but it is increasingly recognized to affect other systems, with cognitive impairment resembling frontotemporal dementia (FTD) in some patients. We report clinical and pathologic findings of a family with ALS due to a truncating mutation, p.Gly141X, in copper/zinc superoxide dismutase (SOD1). The proband presented clinically with FTD and later showed progressive motor neuron disease, while all other family members had early-onset and rapidly progressive ALS without significant cognitive deficits. Pathologic examination of both the proband and her daughter revealed degeneration of corticospinal tracts and motor neurons in brain and spinal cord compatible with ALS. On the other hand, the proband also had neocortical and limbic system degeneration with pleomorphic neuronal cytoplasmic inclusions. Extramotor pathology in her daughter was relatively restricted to the hypothalamus and extrapyramidal system, but not the neocortex. The inclusions in the proband and her daughter were immunoreactive for SOD1, but negative for TAR DNA-binding protein of 43 kDa (TDP-43). In the proband, a number of the neocortical inclusions were immunopositive for α-internexin, initially suggesting a diagnosis of atypical FTLD, but there was no evidence of fused in sarcoma (FUS) immunoreactivity, which is often detected in atypical FTLD. Analogous to atypical FTLD, neuronal inclusions had variable co-localization of SOD1 and α-internexin. The current classification of FTLD is based on the major constituent protein: FTLD-tau, FTLD-TDP-43, and FTLD-FUS. The proband in this family indicates that SOD1, while rare, can also be the substrate of FTLD, in addition to the more common presentation of ALS. The explanation for clinical and pathologic heterogeneity of SOD1 mutations, including the p.Gly141X mutation, remains unresolved.

AB - Amyotrophic lateral sclerosis (ALS) is a degenerative disorder affecting upper and lower motor neurons, but it is increasingly recognized to affect other systems, with cognitive impairment resembling frontotemporal dementia (FTD) in some patients. We report clinical and pathologic findings of a family with ALS due to a truncating mutation, p.Gly141X, in copper/zinc superoxide dismutase (SOD1). The proband presented clinically with FTD and later showed progressive motor neuron disease, while all other family members had early-onset and rapidly progressive ALS without significant cognitive deficits. Pathologic examination of both the proband and her daughter revealed degeneration of corticospinal tracts and motor neurons in brain and spinal cord compatible with ALS. On the other hand, the proband also had neocortical and limbic system degeneration with pleomorphic neuronal cytoplasmic inclusions. Extramotor pathology in her daughter was relatively restricted to the hypothalamus and extrapyramidal system, but not the neocortex. The inclusions in the proband and her daughter were immunoreactive for SOD1, but negative for TAR DNA-binding protein of 43 kDa (TDP-43). In the proband, a number of the neocortical inclusions were immunopositive for α-internexin, initially suggesting a diagnosis of atypical FTLD, but there was no evidence of fused in sarcoma (FUS) immunoreactivity, which is often detected in atypical FTLD. Analogous to atypical FTLD, neuronal inclusions had variable co-localization of SOD1 and α-internexin. The current classification of FTLD is based on the major constituent protein: FTLD-tau, FTLD-TDP-43, and FTLD-FUS. The proband in this family indicates that SOD1, while rare, can also be the substrate of FTLD, in addition to the more common presentation of ALS. The explanation for clinical and pathologic heterogeneity of SOD1 mutations, including the p.Gly141X mutation, remains unresolved.

KW - Amyotrophic lateral sclerosis

KW - Electron microscopy

KW - Frontotemporal lobar degeneration

KW - Immunohistochemistry

KW - Internexin-alpha

KW - Neurofilament

KW - Superoxide dismutase 1

UR - http://www.scopus.com/inward/record.url?scp=84931006172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931006172&partnerID=8YFLogxK

U2 - 10.1007/s00401-015-1431-2

DO - 10.1007/s00401-015-1431-2

M3 - Article

C2 - 25917047

AN - SCOPUS:84931006172

VL - 130

SP - 145

EP - 157

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 1

ER -